Enanta Pharma's upcoming Phase 2b RSV trial results for zelicapavir in high-risk adults generate significant investor interest.
U.S. offers $20 billion aid package to stabilize Argentina, drawing criticism over political ties and China influence.
Rookie Falcons edge rusher James Pearce emerges as a top defensive threat, while the Commanders and Bears seek to bolster their defenses through potential trades.
Enanta Pharma's upcoming Phase 2b RSV trial results for zelicapavir in high-risk adults generate significant investor interest.
U.S. offers $20 billion aid package to stabilize Argentina, drawing criticism over political ties and China influence.
Rookie Falcons edge rusher James Pearce emerges as a top defensive threat, while the Commanders and Bears seek to bolster their defenses through potential trades.